A prospective multicenter study reports that Woven EndoBridge intrasaccular therapy safely and effectively treats unruptured ...

A 65-year-old white woman presented with 9 months of intermittent “kaleidoscopic” visual disturbances and blurred vision upon awakening.Her medical history was significant for hypertension, ...

Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant effects, ...

Recent developments of interest in cardiovascular medicine ...

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...

The Scientia deal follows Medtronic’s announcement in February that it’ll acquire CathWorks for up to $585 million.

Imran Khan is a Pakistan Tehreek-e-Insaf (PTI) leader and the former Pakistan national cricket team captain who is currently ...

Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to ...

VIS-101 targets VEGF-A and ANG-2 with a bispecific tetravalent format designed to increase ligand affinity and binding capacity, aiming to improve anatomic/visual outcomes and extend dosing intervals.

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatm ...

The peripheral vascular device market will rise from $10.4B in 2025 to $14.8B by 2032, driven by drug‑coated balloons, ...

Median exposure reduced to 0 versus lead apron during LAAO, with possible broader applicab ...